IL311354A - polymorphs as ERBB inhibitors - Google Patents

polymorphs as ERBB inhibitors

Info

Publication number
IL311354A
IL311354A IL311354A IL31135424A IL311354A IL 311354 A IL311354 A IL 311354A IL 311354 A IL311354 A IL 311354A IL 31135424 A IL31135424 A IL 31135424A IL 311354 A IL311354 A IL 311354A
Authority
IL
Israel
Prior art keywords
polymorphs
erbb inhibitors
erbb
inhibitors
Prior art date
Application number
IL311354A
Other languages
English (en)
Hebrew (he)
Inventor
Wu-Yan Zhang
Reza Foroughi
Siyi Jiang
Meiqi Li
Juanjuan Shi
Original Assignee
Black Diamond Therapeutics Inc
Zhang wu yan
Reza Foroughi
Siyi Jiang
Meiqi Li
Juanjuan Shi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc, Zhang wu yan, Reza Foroughi, Siyi Jiang, Meiqi Li, Juanjuan Shi filed Critical Black Diamond Therapeutics Inc
Publication of IL311354A publication Critical patent/IL311354A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL311354A 2021-09-21 2022-09-21 polymorphs as ERBB inhibitors IL311354A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163246451P 2021-09-21 2021-09-21
PCT/US2022/044232 WO2023049168A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Publications (1)

Publication Number Publication Date
IL311354A true IL311354A (en) 2024-05-01

Family

ID=83691602

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311354A IL311354A (en) 2021-09-21 2022-09-21 polymorphs as ERBB inhibitors

Country Status (10)

Country Link
US (1) US20240425492A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405350A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534517A (cg-RX-API-DMAC10.html)
KR (1) KR20240099193A9 (cg-RX-API-DMAC10.html)
CN (1) CN119110799A (cg-RX-API-DMAC10.html)
AU (1) AU2022352658A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231697A1 (cg-RX-API-DMAC10.html)
IL (1) IL311354A (cg-RX-API-DMAC10.html)
MX (1) MX2024003475A (cg-RX-API-DMAC10.html)
WO (1) WO2023049168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN122580302A (zh) * 2023-12-21 2026-08-14 黑钻治疗公司 Erbb抑制剂的固体形式
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Also Published As

Publication number Publication date
EP4405350A1 (en) 2024-07-31
KR20240099193A9 (ko) 2025-12-10
MX2024003475A (es) 2024-04-05
KR20240099193A (ko) 2024-06-28
CN119110799A (zh) 2024-12-10
CA3231697A1 (en) 2023-03-30
AU2022352658A1 (en) 2024-03-21
JP2024534517A (ja) 2024-09-20
US20240425492A1 (en) 2024-12-26
WO2023049168A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
KR20240099193A9 (ko) Erbb 억제제로서의 다형체
GB2637108B (en) Novel Compounds
GB202115158D0 (en) Novel compounds
GB202016800D0 (en) Novel compounds
GB202115156D0 (en) Novel compounds
GB202008749D0 (en) Novel compounds
GB202115150D0 (en) Novel compounds
GB2605894B (en) Novel compounds
GB202101734D0 (en) Novel Compounds
GB202106872D0 (en) Novel compounds
HK40114176A (en) Polymorphs as erbb inhibitors
GB202106871D0 (en) Novel compounds
GB202014070D0 (en) Polymorph
GB202014341D0 (en) Novel compounds
GB202118096D0 (en) Novel compounds
GB202117366D0 (en) Novel compounds
GB202113016D0 (en) Novel compounds
GB202110809D0 (en) Novel compounds
GB202109446D0 (en) Novel compounds
GB202108873D0 (en) Novel compounds
GB202101935D0 (en) Novel compounds
GB202101573D0 (en) Novel compounds
GB202101280D0 (en) Novel compounds
GB202019590D0 (en) Novel Compounds
GB202019588D0 (en) Novel Compounds